The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists.
Hastings
Kenneth L
KL
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D002839:Chromans / Q000009:adverse effects; D002986:Clinical Trials as Topic; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism; D011237:Predictive Value of Tests; D051381:Rats; D045162:Thiazolidinediones / Q000009:adverse effects; D014018:Tissue Distribution; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D000077288:Troglitazone